Full Press Release Details
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life.
BIIB
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Key Takeaway: New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis